HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Abstract
Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme. Patients with AERD on average have more severe respiratory disease compared with patients with chronic rhinosinusitis with nasal polyps and/or asthma alone. Although patients with AERD traditionally develop significant upper and lower respiratory tract symptoms on ingestion of cycloxgenase-1 inhibitors, most of these same patients report clinical benefit when desensitized to aspirin and maintained on daily aspirin therapy. This Work Group Report provides a comprehensive review of aspirin challenges, aspirin desensitizations, and maintenance aspirin therapy in patients with AERD. Identification of appropriate candidates, indications and contraindications, medical and surgical optimization strategies, protocols, medical management during the desensitization, and recommendations for maintenance aspirin therapy following desensitization are reviewed. Also included is a summary of studies evaluating the clinical efficacy of aspirin therapy after desensitization as well as a discussion on the possible cellular and molecular mechanisms explaining how this therapy provides unique benefit to patients with AERD.
AuthorsWhitney W Stevens, Elina Jerschow, Alan P Baptist, Larry Borish, John V Bosso, Kathleen M Buchheit, Katherine N Cahill, Paloma Campo, Seong H Cho, Anjeni Keswani, Joshua M Levy, Anil Nanda, Tanya M Laidlaw, Andrew A White
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 147 Issue 3 Pg. 827-844 (03 2021) ISSN: 1097-6825 [Electronic] United States
PMID33307116 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Allergens
  • Anti-Inflammatory Agents
  • Aspirin
Topics
  • Administration, Oral
  • Algorithms
  • Allergens (immunology)
  • Animals
  • Anti-Inflammatory Agents (immunology, therapeutic use)
  • Aspirin (immunology, therapeutic use)
  • Asthma, Aspirin-Induced (diagnosis, immunology, therapy)
  • Chronic Disease
  • Desensitization, Immunologic (methods)
  • Humans
  • Rhinitis (diagnosis, immunology, therapy)
  • Sinusitis (diagnosis, immunology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: